FDA Joint Committee Recommends Approval of Uloric (Febuxostat) Tablets

Posted by Danielle Stewart on Posted on

On January 11th, 2019, Takeda Pharmaceuticals appeared before a joint session of the Arthritis Advisory and the Drug Safety and Risk Management Advisory Committees. They were seeking approval for their supplemental new drug application for Uloric tablets (sNDA 021-856). Uloric, a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout,
Read More